Concepts (131)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ataxia | 7 | 2020 | 76 | 3.810 |
Why?
|
| Tremor | 7 | 2020 | 104 | 3.740 |
Why?
|
| Fragile X Syndrome | 8 | 2020 | 188 | 3.710 |
Why?
|
| Accidental Falls | 3 | 2020 | 110 | 1.310 |
Why?
|
| Fragile X Mental Retardation Protein | 5 | 2016 | 115 | 1.310 |
Why?
|
| Gait | 5 | 2020 | 412 | 1.290 |
Why?
|
| Postural Balance | 3 | 2021 | 117 | 1.280 |
Why?
|
| Heterozygote | 4 | 2020 | 100 | 1.160 |
Why?
|
| Gait Disorders, Neurologic | 2 | 2020 | 133 | 1.120 |
Why?
|
| Walking Speed | 2 | 2020 | 41 | 0.810 |
Why?
|
| Psychomotor Performance | 2 | 2020 | 205 | 0.790 |
Why?
|
| Databases, Factual | 2 | 2021 | 347 | 0.770 |
Why?
|
| Walking | 2 | 2022 | 253 | 0.750 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.670 |
Why?
|
| Nootropic Agents | 1 | 2020 | 14 | 0.670 |
Why?
|
| Movement Disorders | 2 | 2020 | 66 | 0.660 |
Why?
|
| Attention | 1 | 2020 | 124 | 0.650 |
Why?
|
| Huntington Disease | 1 | 2020 | 48 | 0.640 |
Why?
|
| Phenotype | 3 | 2016 | 312 | 0.630 |
Why?
|
| Male | 16 | 2021 | 14772 | 0.600 |
Why?
|
| Cyclodextrins | 1 | 2018 | 8 | 0.580 |
Why?
|
| Executive Function | 1 | 2018 | 111 | 0.580 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 879 | 0.570 |
Why?
|
| Niemann-Pick Disease, Type C | 1 | 2018 | 24 | 0.570 |
Why?
|
| Female | 15 | 2021 | 15212 | 0.550 |
Why?
|
| Humans | 15 | 2022 | 27072 | 0.450 |
Why?
|
| Receptors, Estrogen | 5 | 1995 | 65 | 0.440 |
Why?
|
| Hyperkinesis | 1 | 2013 | 8 | 0.440 |
Why?
|
| Middle Aged | 8 | 2020 | 8923 | 0.430 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 18 | 0.430 |
Why?
|
| Aged | 8 | 2022 | 8997 | 0.430 |
Why?
|
| Adolescent | 4 | 2021 | 2172 | 0.400 |
Why?
|
| Cognition Disorders | 1 | 2018 | 985 | 0.380 |
Why?
|
| Biomechanical Phenomena | 4 | 2022 | 644 | 0.350 |
Why?
|
| Reference Values | 2 | 2021 | 186 | 0.350 |
Why?
|
| Child | 3 | 2021 | 1295 | 0.350 |
Why?
|
| Walk Test | 2 | 2020 | 10 | 0.340 |
Why?
|
| Neuropsychological Tests | 3 | 2020 | 1196 | 0.340 |
Why?
|
| Adult | 5 | 2021 | 7831 | 0.320 |
Why?
|
| Child, Preschool | 2 | 2021 | 641 | 0.310 |
Why?
|
| Young Adult | 3 | 2021 | 1994 | 0.300 |
Why?
|
| Hippocampus | 4 | 1995 | 273 | 0.300 |
Why?
|
| Shoes | 1 | 2022 | 33 | 0.190 |
Why?
|
| Case-Control Studies | 2 | 2020 | 587 | 0.180 |
Why?
|
| Parkinson Disease | 2 | 2020 | 670 | 0.180 |
Why?
|
| Cognition | 2 | 2020 | 1339 | 0.180 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 4 | 0.170 |
Why?
|
| Time and Motion Studies | 1 | 2020 | 19 | 0.170 |
Why?
|
| Glucosylceramidase | 1 | 2020 | 15 | 0.170 |
Why?
|
| Foot | 1 | 2020 | 44 | 0.170 |
Why?
|
| Retrospective Studies | 2 | 2020 | 3538 | 0.170 |
Why?
|
| Arm | 1 | 2020 | 83 | 0.160 |
Why?
|
| Range of Motion, Articular | 2 | 2020 | 708 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2020 | 420 | 0.150 |
Why?
|
| Mutation | 1 | 2020 | 348 | 0.150 |
Why?
|
| Animals | 7 | 2016 | 3642 | 0.150 |
Why?
|
| Infusions, Spinal | 1 | 2018 | 6 | 0.150 |
Why?
|
| Spinal Puncture | 1 | 2018 | 25 | 0.140 |
Why?
|
| Motor Activity | 1 | 2020 | 323 | 0.140 |
Why?
|
| Brain Tissue Transplantation | 2 | 1993 | 15 | 0.130 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 4777 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2016 | 32 | 0.130 |
Why?
|
| Posture | 1 | 2016 | 63 | 0.130 |
Why?
|
| Time Factors | 1 | 2020 | 1433 | 0.130 |
Why?
|
| Computers | 1 | 2015 | 17 | 0.130 |
Why?
|
| Early Diagnosis | 1 | 2015 | 57 | 0.120 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2015 | 45 | 0.120 |
Why?
|
| Neuroimaging | 1 | 2016 | 126 | 0.120 |
Why?
|
| Animals, Newborn | 3 | 1993 | 43 | 0.120 |
Why?
|
| Reaction Time | 1 | 2015 | 102 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 68 | 0.120 |
Why?
|
| Cerebral Cortex | 2 | 1993 | 155 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2015 | 260 | 0.120 |
Why?
|
| Sexual Behavior, Animal | 1 | 1994 | 1 | 0.120 |
Why?
|
| Pituitary-Adrenal System | 1 | 1994 | 13 | 0.120 |
Why?
|
| Receptors, Progesterone | 1 | 1994 | 26 | 0.120 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1994 | 23 | 0.120 |
Why?
|
| Disability Evaluation | 1 | 2016 | 264 | 0.120 |
Why?
|
| Arousal | 1 | 1994 | 50 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 1995 | 310 | 0.110 |
Why?
|
| Disease Progression | 1 | 2016 | 673 | 0.110 |
Why?
|
| Rats | 6 | 1995 | 664 | 0.110 |
Why?
|
| Task Performance and Analysis | 1 | 2013 | 47 | 0.110 |
Why?
|
| Cerebellar Diseases | 1 | 2013 | 8 | 0.110 |
Why?
|
| Movement | 1 | 2013 | 112 | 0.100 |
Why?
|
| Neurons | 2 | 1995 | 339 | 0.090 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 595 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 1112 | 0.090 |
Why?
|
| Treatment Outcome | 1 | 2020 | 3485 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2016 | 1890 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 1144 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1995 | 332 | 0.050 |
Why?
|
| Fetal Tissue Transplantation | 2 | 1993 | 22 | 0.050 |
Why?
|
| Estradiol | 2 | 1993 | 53 | 0.050 |
Why?
|
| Mechanical Phenomena | 1 | 2022 | 25 | 0.050 |
Why?
|
| Pregnancy | 2 | 1993 | 336 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 676 | 0.040 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 1995 | 1 | 0.030 |
Why?
|
| N-Methylaspartate | 1 | 1995 | 3 | 0.030 |
Why?
|
| Receptors, AMPA | 1 | 1995 | 7 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1995 | 11 | 0.030 |
Why?
|
| Sex Differentiation | 1 | 1995 | 2 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1995 | 23 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1995 | 27 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1995 | 49 | 0.030 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 1994 | 8 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1994 | 7 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1992 | 26 | 0.030 |
Why?
|
| Cytosol | 2 | 1992 | 42 | 0.030 |
Why?
|
| Gene Expression | 1 | 1995 | 199 | 0.030 |
Why?
|
| Brain Mapping | 1 | 1994 | 147 | 0.030 |
Why?
|
| Transplantation, Heterotopic | 1 | 1993 | 7 | 0.030 |
Why?
|
| Preoptic Area | 1 | 1993 | 6 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 1993 | 81 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 1994 | 271 | 0.030 |
Why?
|
| Aging | 2 | 1993 | 1544 | 0.030 |
Why?
|
| Calcium | 1 | 1995 | 371 | 0.030 |
Why?
|
| Age Factors | 1 | 1995 | 766 | 0.030 |
Why?
|
| Diethylstilbestrol | 1 | 1990 | 1 | 0.020 |
Why?
|
| Ethinyl Estradiol | 1 | 1990 | 2 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 1990 | 4 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 1990 | 3 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1990 | 83 | 0.020 |
Why?
|
| Kinetics | 1 | 1990 | 188 | 0.020 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 1061 | 0.020 |
Why?
|
| Sex Factors | 1 | 1990 | 464 | 0.020 |
Why?
|
| Receptors, Glutamate | 1 | 1995 | 2 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 1995 | 24 | 0.010 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1995 | 26 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1995 | 520 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1992 | 278 | 0.010 |
Why?
|